IRON News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

IR

Mkt Cap

$2.18B

Volume

480.04K

Next Earnings

November 5th

Loading chart

IR

IRONDisc Medicine, Inc. Common Stock

IRON

Pay with—

Available Balance0.00

IR

Mkt Cap

$2.17B

Volume

480.04K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your RightsThe Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) following an FDA Complete Response Letter on February 13, 2026, regarding its bitopertin program. The FDA stated it could not approve the new drug application due to uncertainties requiring additional evidence. Disc Medicine's stock price fell 22% on the news. The firm is preparing a class action lawsuit to recover investor losses.GlobeNewswire Inc. · Oct 5, 2026

Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your RightsThe Rosen Law Firm is investigating potential securities claims on behalf of Disc Medicine shareholders after the FDA issued a Complete Response Letter on February 13, 2026, regarding the company's bitopertin program, citing uncertainties requiring additional evidence. The stock fell 22% following the announcement. Investors who suffered losses are encouraged to join a prospective class action.GlobeNewswire Inc. · Sep 22, 2026

Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your RightsThe Rosen Law Firm is investigating potential securities claims on behalf of Disc Medicine shareholders after the FDA issued a Complete Response Letter rejecting the company's bitopertin drug application on February 13, 2026. The rejection, citing uncertainties requiring additional evidence, caused Disc Medicine's stock to plummet 22%. The firm is preparing a class action lawsuit to recover investor losses.GlobeNewswire Inc. · Sep 12, 2026

Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your RightsDisc Medicine, Inc. (NASDAQ: IRON) received a Complete Response Letter from the FDA on February 13, 2026, rejecting its bitopertin drug application due to uncertainties requiring additional evidence. The stock fell 22% following the announcement. Rosen Law Firm is investigating potential securities fraud claims and preparing a class action lawsuit on behalf of affected shareholders.GlobeNewswire Inc. · Sep 4, 2026

Disc Medicine to Participate in Upcoming Investor ConferencesDisc Medicine (NASDAQ: IRON), a clinical-stage biopharmaceutical company focused on hematologic diseases, announced participation in four major investor conferences in September 2026. The company also reported completing a Type A FDA meeting on bitopertin with Phase 3 APOLLO study data expected in Q4 2026, which could serve as the basis for a Complete Response Letter (CRL) response.GlobeNewswire Inc. · Sep 2, 2026

Disc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual MeetingDisc Medicine announced it will present clinical data from multiple programs at the SOHO 2026 Annual Meeting in Houston, including initial Phase 2 RESTORE-PV trial data for DISC-3405 in polycythemia vera patients and efficacy data from the RALLY-MF trial of DISC-0974 for myelofibrosis-associated anemia. The oral presentations are scheduled for September 9-12, 2026.GlobeNewswire Inc. · Aug 31, 2026

Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your RightsThe Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) following an FDA Complete Response Letter on February 13, 2026, regarding its bitopertin program. The FDA stated it could not approve the new drug application due to uncertainties requiring additional evidence. Disc Medicine's stock price fell 22% on the news. Investors who purchased Disc Medicine securities may be eligible to join a class action lawsuit seeking recovery of losses.GlobeNewswire Inc. · Aug 29, 2026

BellRing Investor News: If You Own Stock in BellRing Brands, Inc., You Are Encouraged to Contact The Rosen Law Firm About Your RightsRosen Law Firm, a securities litigation firm, is investigating potential fiduciary duty breaches and securities claims against BellRing Brands, Intuit, and Disc Medicine. Current shareholders are encouraged to contact the firm to learn about their legal rights regarding potential losses.GlobeNewswire Inc. · Aug 29, 2026

Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your RightsThe Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) following an FDA Complete Response Letter on February 13, 2026, regarding its bitopertin program. The FDA stated it could not approve the new drug application due to uncertainties requiring additional evidence. Disc Medicine's stock price fell 22% on the news. Investors who suffered losses are encouraged to join a prospective class action.GlobeNewswire Inc. · Aug 26, 2026

BellRing Investor News: If You Own Stock in BellRing Brands, Inc., You Are Encouraged to Contact The Rosen Law Firm About Your RightsRosen Law Firm is investigating potential fiduciary duty breaches and securities claims against BellRing Brands, Primoris Services Corporation, and Disc Medicine. The firm is encouraging shareholders who have suffered losses to contact them before important legal deadlines.GlobeNewswire Inc. · Aug 24, 2026

to start trading

IR

IRONDisc Medicine, Inc. Common Stock

IRON

Pay with—

Available Balance0.00

Your PositionYou don't own any IRON yet.

Related Tickers

Earnings